Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 15:12:685344.
doi: 10.3389/fimmu.2021.685344. eCollection 2021.

Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination

Affiliations
Review

Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination

Hiroyuki Oshiumi. Front Immunol. .

Abstract

Vaccination is the best prophylaxis for the prevention of infectious diseases, including coronavirus disease 2019. However, the efficacy of vaccines and onset of adverse reactions vary among individuals. Circulating extracellular vesicles (EVs) regulate the immune responses after vaccination by delivering microRNAs (miRNAs) to myeloid and lymphoid cells. Among these, miR-192 levels in serum EVs increase with aging, in an IL-6-dependent manner, reducing excessive IL-6 expression in aged mice, creating a negative feedback loop. Excessive IL-6 expression reduces vaccination efficacy in aged mice, while EV miR-192 improves efficacy in these aged mice as well, making this miRNA an interesting focus of study. miR-21 levels in serum EVs also increase with aging, and regulates the expression of IL-12 required for Th1 responses; therefore, EV miR-21 is expected to regulate vaccine efficacy. miR-451a, another important miRNA, is abundant in serum EVs and controls the expression of cytokines, such as type I interferon and IL-6. However, levels differ among individuals and correlate with local inflammatory symptoms experienced after a seasonal flu vaccination. These findings suggest the importance of EV miRNAs as a tool to improve vaccine efficacy and also as biomarkers to predict the immune response and adverse reactions after vaccinations.

Keywords: cytokine; extracellular vesicle; innate immunity; microRNA; vaccine.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
EV miRNAs regulate cytokine expression in response to vaccines. EVs deliver miR-451a, miR-192, and miR-21 to recipient cells, such as macrophages. Vaccine adjuvants then stimulate these macrophages and dendritic cells, resulting in the production of pro-inflammatory cytokines. miR-451a attenuates type I IFN and IL-6 expression in macrophages, and miR-192 reduces the expression of IL-6. miR-21 has the ability to attenuate the IL-12 expression. miR-192 and miR-21 levels in EVs increase with aging in an IL-6-dependent manner. Serum IL-6 levels are increased with aging, and thus constituting a miR-192-dependen negative feedback loop.

References

    1. Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega-Rivera OA, et al. . Covid-19 Vaccine Development and a Potential Nanomaterial Path Forward. Nat Nanotechnol (2020) 15:646–55. 10.1038/s41565-020-0737-y - DOI - PubMed
    1. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. . Evaluation of the Mrna-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates. N Engl J Med (2020) 383:1544–55. 10.1056/NEJMoa2024671 - DOI - PMC - PubMed
    1. Coffman RL, Sher A, Seder RA. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity (2010) 33:492–503. 10.1016/j.immuni.2010.10.002 - DOI - PMC - PubMed
    1. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-biased Agonist of TLR4. Science (2007) 316:1628–32. 10.1126/science.1138963 - DOI - PubMed
    1. Temizoz B, Kuroda E, Ishii KJ. Vaccine Adjuvants as Potential Cancer Immunotherapeutics. Int Immunol (2016) 28:329–38. 10.1093/intimm/dxw015 - DOI - PMC - PubMed

Publication types

LinkOut - more resources